Skip to content

The effectof omega 3 fatty acids supplemention on uterine prostaglandineE2 and aromatase P450 in patients with leiomyoma

The effectof omega 3 fatty acids supplemention on uterine prostaglandineE2 and aromatase P450 in patients with leiomyoma

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130115012146N7
Enrollment
20
Registered
2020-07-05
Start date
2020-06-21
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Myoma. Leiomyoma of uterus

Interventions

Intervention 1: Intervention group: we are going to take uterine flushing and uterine biopsy in special days of menstrual cycles . then we are going to give omega 3 for three months for intervention g

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age range 40-25 years Intra molar myomas are less than 50% prominent in the uterine cavity. Patients with leiomyoma who have been treated for myomas have not used hormonal drugs, including GNRH agonists, progesterone, and so on.

Exclusion criteria

Exclusion criteria: Patients with uterine obstruction, AUB, PCO and , taking hormonal drugs and Patients with hormonal disorders Patients with Polycystic ovary syndrome Patients with abnormal uterine bleeding Patients with metabolic disorders Patients taking hormonal drugs. Patients with uterine polyps

Design outcomes

Primary

MeasureTime frame
Size of myoma. Timepoint: Three months after taking the drug. Method of measurement: sonography.;Number of uterine fibroids. Timepoint: Three months after taking the drug. Method of measurement: sonography.

Secondary

MeasureTime frame
PGE2 levels in uterine fluid. Timepoint: Three months after taking the drug. Method of measurement: Measurement in the laboratory.;The amount of aromatase and PGES genes. Timepoint: Three months after taking the drug. Method of measurement: Measurement in the laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Farzadi Laaya

Tabriz University of Medical Sciences

lahroudin@gmail.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026